[1]
|
Anderson, D.C., Halperin, J.L., Hart, R.G., Mcanulty, J.H. and Sherman, D.G. (1998) Patients with Nonvalvular Atrial Fibrillation at Low Risk of Stroke during Treatment with Aspirin—Stroke Prevention in Atrial Fibrillation III Study. JAMA: The Journal of the American Medical Association, 279, 1273-1277. https://doi.org/10.1001/jama.279.16.1273
|
[2]
|
Lip, G., Lip, G.Y.H., Freedman, B., Caterina, R.D. and Potpara, T.S. (2017) Stroke Prevention in Atrial Fibrillation: Past, Present and Future. Comparing the Guidelines and Practical Deci-sion-Making. Thrombosis & Haemostasis, 117, 1230-1239. https://doi.org/10.1160/TH16-11-0876
|
[3]
|
Lega, J.C., Bertoletti, L., Gremillet, C., Chapelle, C. and Laporte, S. (2014) Consistency of Safety and Efficacy of New Oral Anti-coagulants across Subgroups of Patients with Atrial Fibrillation. PLOS ONE, 9, e91398.
https://doi.org/10.1371/journal.pone.0091398
|
[4]
|
Ji, C., Wu, S., Shi, J., Huang, Z., Chen, S., Wang, G. and Cui, W. (2020) Baseline CHADS2 Score and Risk of Cardiovascular Events in the Population without Atrial Fibrillation. American Journal of Cardiology, 129, 30-35.
https://doi.org/10.1016/j.amjcard.2020.05.035
|
[5]
|
Lévy, S., Steinbeck, G., Santini, L., Nabauer, M., Maceda, D.P., Kantharia, B.K., Saksena, S. and Cappato, R. (2022) Management of Atrial Fibrillation: Two Decades of Progress—A Scientific Statement from the European Cardiac Arrhythmia Society. Journal of Interventional Cardiac Electrophysiology, 65, 287-326.
https://doi.org/10.1007/s10840-022-01195-z
|
[6]
|
Ukaji, T., Ishikawa, T., Nakamura, H., Mizutani, Y., Yamada, K., Shimura, M., Kondo, Y., Tamura, Y., Koshikawa, Y., Hisauchi, I., Nakahara, S., Itabashi, Y., Kobayashi, S. and Taguchi, I. (2023) Prognostic Impacts of CHADS2, CHA2DS2-VASc, and CHA2DS2-VASc-HS Scores on Clinical Outcomes after Elective Drug-Eluting Stent Placement for De Novo Coronary Stenosis. Circulation Reports, 5, 123-132. https://doi.org/10.1253/circrep.CR-22-0120
|
[7]
|
Investigators AF (1994) Risk Factors for Stroke and Efficacy of Antithrombotic Therapy in Atrial Fibrillation. Analysis of Pooled Data from Five Randomized Controlled Trials. Archives of Internal Medicine, 154, 1449-1457.
https://doi.org/10.1001/archinte.1994.00420130036007
|
[8]
|
Hart, R., Pearce, L., McBride, R., Rothbart, R. and Asinger, R. (1999) Factors Associated with Ischemic Stroke during Aspirin Therapy in Atrial Fibrillation: Analysis of 2012 Participants in the SPAF I-III Clinical Trials. The Stroke Prevention in Atrial Fibrillation (SPAF) Investigators. Stroke, 30, 1223-1229. https://doi.org/10.1161/01.STR.30.6.1223
|
[9]
|
Gage, B.F., Waterman, A.D., Shannon, W., Boechler, M., Rich, M.W. and Radford, M.J. (2001) Validation of Clinical Classification Schemes for Predicting Stroke: Results from the National Registry of Atrial Fibrillation. ACC Current Journal Review, 10, 20-21. https://doi.org/10.1016/S1062-1458(01)00458-5
|
[10]
|
Gage, B., van Walraven, C., Pearce, L., et al. (2004) Select-ing Patients with Atrial Fibrillation for Anticoagulation: Stroke Risk Stratification in Patients Taking Aspirin. Circulation, 110, 2287-2292.
https://doi.org/10.1161/01.CIR.0000145172.55640.93
|
[11]
|
Fuster, V., Rydén, L., Cannom, D.S., et al. (2006) ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Car-diology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Pa-tients with Atrial Fibrillation): Developed in Collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. European Heart Journal, 38, 1231-1265.
https://doi.org/10.1161/CIRCULATIONAHA.106.177292
|
[12]
|
Coppens, M., Eikelboom, J., Hart, R., et al. (2013) The CHA2DS2-VASc Score Identifies Those Patients with Atrial Fibrillation and a CHADS2 Score of 1 Who Are Un-likely to Benefit from Oral Anticoagulant Therapy. European Heart Journal, 34, 170-176. https://doi.org/10.1093/eurheartj/ehs314
|
[13]
|
历治潼, 赵玫. CHADS2评分及其衍生评分对冠状动脉病变严重程度的预测价值[J]. 山东医药, 2019, 59(4): 6-9.
|
[14]
|
Borre, E.D., Goode, A., Raitz, G., Shah, B. and Sanders, G.D. (2018) Predicting Thromboembolic and Bleeding Event Risk in Patients with Non-Valvular Atrial Fibrillation: A Sys-tematic Review. Thrombosis and Haemostasis, 118, 2171-2187. https://doi.org/10.1055/s-0038-1675400
|
[15]
|
Olesen, J.B., Torp-Pedersen, C., Hansen, M.L. and Lip, G. (2012) The Value of the CHA2DS2-VASc Score for Refining Stroke Risk Stratification in Patients with Atrial Fibrillation with a CHADS2 Score 0-1: A Nationwide Cohort Study. Thrombosis and Haemostasis, 107, 1172-1179. https://doi.org/10.1160/TH12-03-0175
|
[16]
|
Camm, A.J., Kirchhof, P., Savelieva, I., et al. (2010) Guidelines for the Management of Atrial Fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). European Heart Journal, 31, 2369-2429.
|
[17]
|
National Collaborating Centre for Chronic Conditions (UK) (2006) Atrial Fibrillation: National Clinical Guideline for Management in Primary and Secondary Care. Clinical Medicine, 7, 379.
|
[18]
|
Singer, D.E., Albers, G.W., Dalen, J.E., et al. (2008) Antithrombotic Therapy in Atrial Fibrilla-tion: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest, 133, 546S-592S.
|
[19]
|
Wang, T.J., et al. (2003) A Risk Score for Predicting Stroke or Death in Individuals with New-Onset Atrial Fibrillation in the Community. The Framingham Heart Study. ACC Current Journal Review, 12, 54.
https://doi.org/10.1016/j.accreview.2003.09.035
|
[20]
|
Deirdre, L. and Gregory, L. (2009) Female Gender Is a Risk Factor for Stroke and Thromboembolism in Atrial Fibrillation Patients. Thrombosis & Haemostasis, 102, 802-805. https://doi.org/10.1160/TH09-02-0106
|
[21]
|
Fang, M.C. (2005) Gender Differences in the Risk of Ischemic Stroke and Peripheral Embolism in Atrial Fibrillation: The Anticoagulation and Risk Factors In Atrial Fibrillation (ATRIA) Study. Circulation, 112, 1687-1691.
https://doi.org/10.1161/CIRCULATIONAHA.105.553438
|
[22]
|
Lip, G., Nieuwlaat, R., Pisters, R., Lane, D. and Crijns, H. (2010) Refining Clinical Risk Stratification for Predicting Stroke and Thromboembolism in Atrial Fibrillation Using a Novel Risk Factor-Based Approach: The Euro Heart Survey on Atrial Fibrillation. Chest, 137, 263-272. https://doi.org/10.1378/chest.09-1584
|
[23]
|
Hart, R., Pearce, L., Halperin, J. and Miller, V. (1994) Aspirin in El-derly Atrial Fibrillation Patients. Stroke, 25, 1525-1526. https://doi.org/10.1161/01.STR.25.7.1525
|
[24]
|
Friberg, L., Benson, L., Rosenqvist, M. and Lip, G. (2012) Assessment of Female Sex as a Risk Factor in Atrial Fibrillation in Swe-den: Nationwide Retrospective Cohort Study. BMJ (Clinical Research ed), 344, e3522.
https://doi.org/10.1136/bmj.e3522
|
[25]
|
Avgil Tsadok, M., Jackevicius, C., Rahme, E., Humphries, K., Behlouli, H. and Pilote, L. (2012) Sex Differences in Stroke Risk among Older Patients with Recently Diagnosed Atrial Fibrillation. JAMA, 307, 1952-1958.
https://doi.org/10.1001/jama.2012.3490
|
[26]
|
Nielsen, P., Skjøth, F., Overvad, T., Larsen, T. and Lip, G. (2018) Female Sex Is a Risk Modifier Rather than a Risk Factor for Stroke in Atrial Fibrillation: Should We Use a CHADS2-VA Score Rather than CHA2DS2-VASc? Circulation, 137, 832-840. https://doi.org/10.1161/CIRCULATIONAHA.117.029081
|
[27]
|
Nielsen, P. and Overvad, T. (2020) Female Sex as a Risk Modifier for Stroke Risk in Atrial Fibrillation: Using CHA2DS2-VASc versus CHA2DS2-VA for Stroke Risk Stratification in Atrial Fibrillation: A Note of Caution. Thrombosis and Haemostasis, 120, 894-898. https://doi.org/10.1055/s-0040-1710014
|
[28]
|
Guo, Y., Apostolakis, S., Blann, A., et al. (2013) Validation of Con-temporary Stroke and Bleeding Risk Stratification Scores in Non-Anticoagulated Chinese Patients with Atrial Fibrillation. International Journal of Cardiology, 168, 904-909.
https://doi.org/10.1016/j.ijcard.2012.10.052
|
[29]
|
Siu, C., Lip, G., Lam, K. and Tse, H. (2014) Risk of Stroke and Intracranial Hemorrhage in 9727 Chinese with Atrial Fibrillation in Hong Kong. Heart Rhythm, 11, 1401-1408. https://doi.org/10.1016/j.hrthm.2014.04.021
|
[30]
|
Lin, L., Lee, C., Yu, C., et al. (2011) Risk Factors and Incidence of Ischemic Stroke in Taiwanese with Nonvalvular Atrial Fibrillation—A Nation Wide Database Analysis. Atherosclero-sis, 217, 292-295.
https://doi.org/10.1016/j.atherosclerosis.2011.03.033
|
[31]
|
Shao, X.H., Yang, Y.M., Zhu, J., Yu, L.T. and Liu, L.S. (2020) Increased Mortality in Patients with Secondary Diagnosis of Atrial Fibrillation: Report from Chinese AF Registry. Annals of Noninvasive Electrocardiology, 25, e12774.
https://doi.org/10.1111/anec.12774
|
[32]
|
Choi, S., Kim, M., Kim, H., et al. (2022) Validation of the CHA2DS2-VA Score (Excluding Female Sex) in Nonvalvular Atrial Fibrillation Patients: A Nationwide Population-Based Study. Jour-nal of Clinical Medicine, 11, Article No. 1823. https://doi.org/10.3390/jcm11071823
|
[33]
|
Suzuki, S., Yamashita, T., Okumura, K., et al. (2015) Incidence of Ischemic Stroke in Japanese Patients with Atrial Fibrillation Not Receiving An-ticoagulation Therapy. Circulation Journal, 79, 432-438.
https://doi.org/10.1253/circj.CJ-14-1131
|
[34]
|
Abe, H. and Koretsune, Y. (2015) New Modified CHA2DS2-VA Scoring System for Japanese Patients with Non-Valvular Atrial Fibrillation. Circulation Journal: Official Journal of the Japanese Circulation Society, 79, 1682-1684.
https://doi.org/10.1253/circj.CJ-15-0653
|
[35]
|
Tomita, H., Okumura, K., Inoue, H., et al. (2015) Validation of Risk Scoring System Excluding Female Sex From CHA2DS2-VASc in Japanese Patients with Nonvalvular Atrial Fibrilla-tion—Subanalysis of the J-RHYTHM Registry. Circulation Journal: Official Journal of the Japanese Circulation Society, 79, 1719-1726.
https://doi.org/10.1253/circj.CJ-15-0095
|
[36]
|
Chao, T.F., Joung, B., Takahashi, Y., Lim, T.W., Choi, E.K., Chan, Y.H., Guo, Y., Sriratanasathavorn, C., Oh, S., Okumura, K. and Lip, G.Y.H. (2021) 2021 Focused Update of the 2017 Consensus Guidelines of the Asia Pacific Heart Rhythm Society (APHRS) on Stroke Prevention in Atrial Fibrillation. Journal of Arrhythmia, 37, 1389-1426.
https://doi.org/10.1002/joa3.12652
|
[37]
|
Ono, K., Iwasaki, Y.K., Akao, M., Ikeda, T., et al. (2022) JCS/JHRS 2020 Guideline on Pharmacotherapy of Cardiac Arrhythmias. Journal of Arrhythmia, 38, 833-973. https://doi.org/10.1002/joa3.12714
|
[38]
|
Cheung, C.C., Nattel, S., Macle, L. and Andrade, J.G. (2021) Management of Atrial Fibrillation in 2021: An Updated Comparison of the Current CCS/CHRS, ESC, and AHA/ACC/HRS Guide-lines. Canadian Journal of Cardiology, 37, 1607-1618. https://doi.org/10.1016/j.cjca.2021.06.011
|
[39]
|
Doost, A., Alasady, M. and Scott, P. (2019) National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand: Australian Clinical Guidelines for the Diagnosis and Management of Atrial Fibrillation 2018. Heart Lung & Circulation, 28, e106-e107. https://doi.org/10.1016/j.hlc.2018.11.016
|
[40]
|
Mulia, E.P.B. (2023) Gender and Atrial Fibrillation: Revisiting Its Role in Integrated ABC Pathway Management. Heart Vessels, 38, 873-875. https://doi.org/10.1007/s00380-022-02168-y
|